Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
INTERVENTIONAL
Inicio: 9 de mar de 2016
ID: NCT02677896
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
INTERVENTIONAL
Inicio: 6 de feb de 2017
ID: NCT02987543
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
INTERVENTIONAL
Inicio: 19 de oct de 2020
ID: NCT04446117
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
INTERVENTIONAL
Inicio: 1 de ene de 2008
ID: NCT00626548
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus
INTERVENTIONAL
Inicio: 1 de dic de 2007
ID: NCT00502242
Completado
ClinicalTrials.gov
A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis
OBSERVATIONAL
Inicio: 31 de dic de 2013
ID: NCT02066961
Completado
Fase 3
ClinicalTrials.gov
Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
INTERVENTIONAL
Inicio: 1 de jul de 2010
ID: NCT01057810
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)
INTERVENTIONAL
Inicio: 28 de sept de 2025
ID: NCT07028853
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
INTERVENTIONAL
Inicio: 24 de ene de 2024
ID: NCT06225596
Activo, no recluta
ClinicalTrials.gov
A Study Comparing Bi-parametric MRI to Multi-parametric MRI in the Diagnosis of Clinically Significant Prostate Cancer
INTERVENTIONAL
Inicio: 22 de mar de 2022
ID: NCT04571840
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma
INTERVENTIONAL
Inicio: 24 de sept de 2019
ID: NCT04003636
Completado
Fase 3
ClinicalTrials.gov
A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
INTERVENTIONAL
Inicio: 12 de sept de 2014
ID: NCT02200614
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy
INTERVENTIONAL
Inicio: 21 de may de 2021
ID: NCT04810078
Completado
Fase 3
ClinicalTrials.gov
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
INTERVENTIONAL
Inicio: 31 de oct de 2013
ID: NCT02003924
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Multinational Study to Assess the Efficacy and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenously Administered Imipenem-cilastatin in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
INTERVENTIONAL
Inicio: 21 de dic de 2023
ID: NCT06059846
Completado
Fase 3
ClinicalTrials.gov
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor
INTERVENTIONAL
Inicio: 1 de abr de 2010
ID: NCT01063855
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)
INTERVENTIONAL
Inicio: 1 de dic de 2009
ID: NCT01030783
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen
INTERVENTIONAL
Inicio: 1 de ene de 2007
ID: NCT00417079
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
INTERVENTIONAL
Inicio: 6 de nov de 2018
ID: NCT03661320
Terminado
Fase 3
ClinicalTrials.gov
A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections
INTERVENTIONAL
Inicio: 1 de dic de 2010
ID: NCT01110408
Anterior
1
...
9
10
11
...
434
Siguiente
Filtros